Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Thursday, April 19, 2018 · 442,985,287 Articles · 3+ Million Readers

Invivo Robotics Releases the Results of its Control Trial Study

The trial demonstrates that patients treated with Invivo Robotics Patient Monitoring System (IRPMS) are 73% less likely to develop a pressure injury

This study is an important step towards redefining the standard of care for pressure injury prevention.”
— Chen G. Gexin
SHANGHAI, CHINA, March 14, 2018 /EINPresswire.com/ -- Invivo Robotics, one of the pioneers in the rapidly emerging field of robotic-assisted minimally invasive surgery, is pleased to announce that researchers have found that patients treated with IRPMS, a wireless device that is adhered to a patient's chest to monitor the patient's position, orientation, movement and activity, are 72% less likely to develop a pressure injury.
The investigator-initiated randomized control trial (RCT) involved more than 1,000 patients and over 10,000 hours of data was analyzed. The IRPMS sensor was used to help ensure that patients were repositioned with sufficient frequency and quality. The optimized care delivery enabled by IRPMS resulted in a significant reduction in hospital acquired pressure injuries.
Pressure injuries are among the most common and costly hospital-acquired conditions, costing the global healthcare system $80 billion annually. The cost to treat pressure ulcers/injuries across the episode of a wound can be over $50,000 for a full-thickness wound.
“This large randomized controlled trial confirms what has been demonstrated in smaller studies and is consistent with real-world customer experience,” said Chen G. Gexin, MD, PhD, Chief Executive Officer for Invivo Robotics. “This study is an important step towards redefining the standard of care for pressure injury prevention.”
The IRPMS System will be exclusively distributed by Invivo Robotics, also an investor in the technology. Chris Leung, Head of Global Product Development, Invivo Robotics, commented, “This study confirms that the optimized care delivery enabled by IRPMS is translated into a significant reduction in hospital-acquired pressure injuries. We are proud to provide this device, alongside our full suite of pioneering products, to support healthcare professionals and enable them to reduce the human and economic cost of wounds.”

About Invivo Robotics

Invivo Robotics is one of the pioneers in the rapidly emerging field of robotic-assisted minimally invasive surgery. Invivo Robotics serves globally providing technology innovation across cardiac, thoracic, urology, gynecologic, colorectal, pediatric and general surgical disciplines. The Company's surgical systems enables surgeons to operate minimally invasively. At Invivo Robotics, delivering our technology is just the beginning. The company is also committed to delivering the best customer experience. To ensure the customers gain the most utility from their Invivo Robotics systems, the firm offers a comprehensive training and education program and first-rate customer support. Invivo Robotics has strong financial backing of leading global investors.


Kang Yong
Invivo Robotics
1852130-6369
email us here

Powered by EIN Presswire